The HIV-2 genotype and the HIV-1 syncytium-inducing phenotype are associated with a lower virus replication in dendritic cells.
During sexual transmission, HIV infects the mucosal dendritic cells and is transferred to CD4 T cells. Whether HIV variants of a particular genetic (sub)type or phenotype selectively infect dendritic cells (DC) or are preferentially transferred to T cells remains highly controversial. To avoid the cumbersome use of primary dendritic cells, in vitro dendritic cell models were generated from precursors, either hematopoietic progenitor cells (HPC) or monocytes (MO). Productive infection in the dendritic cells and transfer of the virus to T cells was assessed for a range of HIV variants. HPC-derived dendritic cells (HPC-DC) were more susceptible to HIV-1 than to HIV-2 isolates. The HIV-1 group O strains were more productive in HPC-DC than group M, but amongst the latter, no subtype-related difference was observed. Both non-syncytium-inducing (NSI) and SI HIV isolates and lab strains could productively infect HPC-DC, albeit with a different efficiency. Adding blocking antibodies confirmed that both CCR-5 and CXCR-4 co-receptors were functional. Biological HIV-1 clones of the NSI/R5 phenotype infected more readily HPC-DC than SI/X4 clones. MO-derived dendritic cells were, however, more exclusive in their preference for NSI/R5 clones. Some HIV variants, that did not grow readily in HPC-DC alone, could be rescued by adding resting or pre-activated T cells. The present data show that HIV-2 isolates and SI clones replicate less in model-DC, but no preference for a particular HIV-1 subtype was evident. Co-culture with T cells could "correct" a limited growth in dendritic cells. Clearly, both intrinsic dendritic cell susceptibility and enhancement by T cells are explained only partly by HIV genotype and phenotype. The in vitro dendritic cell models seem useful tools to further unravel interactions between HIV, DC, and T cells.
Vanham
G
G
Laboratory of Immunology, Department of Microbiology, Institute of Tropical Medicine, Antwerpen, Belgium. gvanham@itg.be
van Tendeloo
V
V
Willems
B
B
Penne
L
L
Kestens
L
L
Beirnaert
E
E
Fransen
K
K
Heyndrickx
L
L
Zhong
P
P
Davis
D
D
Berneman
Z
Z
van Der Groen
G
G
Van Bockstaele
D
D
D065100:CCR5 Receptor Antagonists; D015496:CD4-Positive T-Lymphocytes / Q000821:virology*; D002454:Cell Differentiation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000187:drug effects / Q000821:virology*; D004797:Enzyme-Linked Immunosorbent Assay; D005838:Genotype; D015726:Giant Cells / Q000821:virology*; D006678:HIV / Q000254:growth & development / Q000472:pathogenicity; D015497:HIV-1 / Q000254:growth & development / Q000472:pathogenicity*; D015498:HIV-2 / Q000254:growth & development / Q000472:pathogenicity*; D006801:Humans; D008264:Macrophages / Q000821:virology; D010641:Phenotype; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014779:Virus Replication
D065100:CCR5 Receptor Antagonists; D019718:Receptors, CXCR4; D014409:Tumor Necrosis Factor-alpha